Lipoleiomyoma is an uncommon neoplasm of the uterus, composed of smooth muscles intermixed with mature adipocytes. These tumors are considered a benign variant of uterine leiomyomas. Herein, we report six cases of lipoleiomyoma experienced in our institution from January 2005 to March 2015. The patients ranged in age from 45 to 70 years; the etiology may be related to estrogen deficiency occurring after menopausal transition. Except for one lipoleiomyoma in the broad ligament, all others were found in the uterine corpus. The presenting symptoms were nonspecific, and most cases were incidentally diagnosed during surgery for other reasons. We performed preoperative imaging studies, including abdominal and pelvic computed tomography and magnetic resonance imaging. Preoperatively, four patients were diagnosed as having a pelvic mass and one patient was diagnosed as having a right ovarian mature teratoma. In one case, we found a gynecologic malignancy (cervical cancer 1A1). Histologically, there was no gross or microscopic contiguity between the lipoleiomyoma and the malignancy. Lipoleiomyomas seem to have a benign clinical course. In our study, there were no recurrences of or deaths attributed to the lipoleiomyomas during a mean follow-up period of 16.17 ± 23.80 months. 
Introduction
Uterine lipoleiomyomas are rare benign neoplasms (incidence rate 0.03%-0.20%), and are recognized as a specific type of leiomyoma. 1 These tumors are composed of an intimate admixture of smooth muscle cells and mature adipocytes. 2 They are most commonly located in the uterine corpus, but rarely may be found in other locations, including the cervix, ovary, broad ligament, and retroperitoneum.
2~4
Most patients are asymptomatic peri or postmenopausal women. Actually, uterine lipoleiomyomas are clinically similar to leiomyomas, and require no treatment if asymptomatic. Moreover, these tumors may be confused with other gynecologic conditions such as mature ovarian teratoma, well-differentiated liposarcoma, and atypical lipoma. 2, 3 Therefore, it is essential to distinguish these tumors from others that require surgical excision. 2 We report six cases treated in our institution in order to contribute to the understanding of the characteristics of these tumors Case Report 7 There is no specific defined percentage of adipocytes that would enable a diagnosis of lipoleiomyoma. 
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The majority of lipoleiomyomas are found in the subserosal or intramural uterine corpus, but some occur in the cervix, ovary, broad ligament, and retroperitoneum.
2~4
Although rare, over 75% of retroperitoneal tumors are malignant. 9, 10 Actually, there is a report on surgery with a preoperative diagnosis mimicking retroperitoneal sarcoma in perimenopausal women; the diagnosis of uterine leiomyoma was confirmed. 11 In our study, there was no retroperitoneal lipoleiomyoma. There was only one case wherein the lipoleiomyoma was located in the broad ligament; in all other cases, it was located in the uterine corpus. 12 If the patient complains of acute and persistent abdominal pain, the possibility of torsion needs to be considered. In reported case of torsion of subserosal leiomyoma, the patient was misdiagnosed as having secondary degeneration of uterine leiomyoma prior to the operation; she had suffered from abdominal pain for 2 weeks before surgery. 13 However, in our cases, most symptoms were nonspecific, except for chronic pelvic pain. If asymptomatic, lipoleiomyomas require no treatment; it is therefore essential to distinguish these tumors from those requiring surgical excision.
Although the pathogenesis of uterine lipoleiomyomas is still ambiguous, it is known that some metabolic disorders, including hyperlipidemia, hypothyroidism, and diabetes However, lipoleiomyosarcomas arising in uterine lipoleiomyomas and intravenous lipoleiomyomatosis have been rarely reported. 18~20 Therefore, patients may be followedup with routine gynecological examinations. 8 Recurrence of some benign tumors after hysterectomy has been reported.
For example, endometriosis occurred in a postmenopausal woman who underwent hysterectomy for uterine myoma 16 years prior. 21 Until now, no recurrence of any benign tumors has been reported after hysterectomy for lipoleiomyomas.
In our study, a mean follow-up period was 16.17 ± 23.80
months. There were no recurrences or deaths attributed to the lipoleiomyomas.
In conclusion, lipoleiomyomas are rare uterine tumors, and are considered a variant of uterine leiomyomas.
Lipoleiomyomas are mostly seen in advanced age, and may be associated with estrogen deficiency after menopausal transition. Although lipoleiomyomas showed a favorable outcome in previous studies, regular follow-up may be needed in managing these patients.
